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Strengths and limitations of this study
 ► The review was conducted following established 
guidelines and a prospectively specified protocol.
 ► The review focused on all-cause outcomes to re-
duce the risk of underestimating the vaccine impact 
that exists due to potential difficulties in identifying 
and accurately recording the cause of hospitalisa-
tion and death in patients with an underlying chronic 
disease.
 ► To reduce the risk of missing relevant studies and 
relevant data and to increase the objectivity of the 
review, two independent reviewers screened the 
studies, extracted data and assessed the risk of bias 
and quality of evidence.
 ► Differences in studies included in meta-analyses, 
publication bias, restriction on the publication lan-
guage and varying response to queries about data 
on liver disease subgroups may have affected the 
effects observed in this review.
 ► Inclusion of non-randomised studies lowers the 
quality of evidence and limits the conclusions that 
can be drawn.
ABSTRACT
Objectives Patients with liver disease frequently require 
hospitalisation with infection often the trigger. Influenza 
vaccination is an effective infection prevention strategy in 
healthy and elderly but is often perceived less beneficial 
in patients with liver disease. We investigated whether 
influenza vaccination triggered serological response and 
prevented hospitalisation and death in liver disease.
Design Systematic review and meta-analysis.
Data sources MEDLINE, EMBASE, PubMed and CENTRAL 
up to January 2019.
Eligibility criteria Randomised or observational studies of 
the effects of influenza vaccine in adults with liver disease.
Data extraction and synthesis Two reviewers screened 
studies, extracted data and assessed risk of bias and 
quality of evidence. Primary outcomes were all-cause 
hospitalisation and mortality. Secondary outcomes 
were cause-specific hospitalisation and mortality, 
and serological vaccine response. Random-effects 
meta-analysis was used to estimate pooled effects of 
vaccination.
Results We found 10 041 unique records, 286 were 
eligible for full-text review and 12 were included. Most 
patients had viral liver disease. All studies were of very 
low quality. Liver patients both with and without cirrhosis 
mounted an antibody response to influenza vaccination, 
and vaccination was associated with a reduction in risk 
of hospital admission from 205/1000 to 149/1000 (risk 
difference −0.06, 95% CI −0.07 to 0.04) in patients 
with viral liver disease. Vaccinated patients were 27% 
less likely to be admitted to hospital compared with 
unvaccinated patients (risk ratio 0.73, 95% CI 0.66 to 
0.80). No effect against all-cause or cause-specific 
mortality or cause-specific hospitalisation was found.
Conclusions The low quantity and quality of the evidence 
means that the protective vaccine effect may be uncertain. 
Considering the high risk of serious health outcomes from 
influenza infection in patients with liver disease and the 
safety and low cost of vaccination, overall, the potential 
benefits of seasonal vaccination both to patients and the 
healthcare systems are likely to outweigh the costs and 
risks associated with vaccination.
PROSPERO registration number CRD42017067277.
InTRODuCTIOn
More than 45 million people globally, 
including >8 million people in the USA and 
Europe, are affected by chronic liver disease.1 
The prevalence of liver disease is increasing, 
driven by obesity and alcohol consumption.2
The progression of liver disease is asso-
ciated with immune dysregulation3–6 and 
complications from common acute infec-
tions such as influenza cause significant 
morbidity and mortality. A twofold increased 
risk of hospital admission for influenza was 
observed in patients with liver disease in 19 
hospitals in Russia, Turkey, China and Spain 
during the 2013/2014 season.7 Similarly, an 
analysis of data on laboratory-confirmed 
influenza cases collected from several WHO 
member states during the 2009 influenza A 
(H1N1) pandemic found patients with liver 
disease to have >5-fold increased risk of influ-
enza-related hospitalisation and over 17-fold 
increased risk of death compared with that 
of healthy individuals.8 Influenza infection, 
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cause collateral liver damage9 and trigger hepatic decom-
pensation in liver disease.10
Influenza vaccine introduces a whole or part of the 
influenza virion into the body stimulating antibody 
production against the virus, similar to an actual infec-
tion. In healthy adult and elderly populations, seasonal 
influenza vaccination is an effective way to prevent influ-
enza infection.11 12 People with liver disease, due to the 
high risk of severe health complications from influenza 
infection, are often a target of influenza vaccination 
policies13 but randomised trials on vaccine effectiveness 
in patients with liver disease are lacking as withholding 
the vaccine may place patients’ safety and health at risk. 
For example, a previous systematic review of randomised 
trials of influenza vaccine effectiveness in patients with 
chronic diseases, conducted in 2011,14 identified only 
one study in patients with liver disease. Observational 
studies offer an alternative way of investigating vaccine 
effectiveness but without randomisation of patients the 
results are vulnerable to confounding and bias, in partic-
ular frailty bias. Frailty bias exist when some or all of the 
reduction in the risk of health complications may be due 
to the preferential receipt of vaccine by individuals who 
are in general more healthy. One solution to minimise 
the effect of frailty bias is to observe the vaccine effect 
both within and outside of the influenza season. If frailty 
bias exist, we would see higher rates of health complica-
tions in unvaccinated individuals outside of the influenza 
season. This would indicate that any protective effect 
observed within the season may be partially or fully due 
to the vaccinated individuals being healthier overall and 
an overestimation of the effect of the vaccine. Finally, in 
addition to measuring clinical outcomes to understand 
the effects of the vaccine, the antibody response elicited 
by the vaccine can be measured and used as a proxy for 
vaccine effectiveness.
There is uncertainty among primary and secondary 
care physicians whether influenza vaccines are able to 
trigger an appropriate antibody response and protect 
patients with liver disease from health complications,15 
and the vaccination coverage is poor. Just over 55% of 
the chronic liver disease respondents to the 2016 US 
National Health Interview Survey16 had been vaccinated 
against influenza in the past 12 months and <50% of 
working-age patients with liver disease registered with 
primary care practitioners in England had received 
influenza vaccination during the 2015/2016 season.17 
To inform vaccination policy and to help guide deci-
sion-making regarding vaccination, our review aims to 
provide a systematic synthesis of the available evidence 
from both observational studies and randomised trials 
on the effectiveness of influenza vaccines to prevent 
serious health outcomes, hospitalisation and death, in 
adults with chronic liver disease. To address uncertainty 
over the vaccines’ ability to trigger antibody response in 
patients with liver disease, we also assess the effects of 




This systematic review and meta-analysis followed the 
Preferred Reporting Items for Systematic Review and 
Meta-Analyses guidelines.18 The review protocol was spec-
ified in advance as part of a wider review plan that also 
includes a study of the effectiveness of pneumococcal 
vaccine. The protocol was registered in PROSPERO 13 
June 2017 (registration number CRD42017067277) and 
published after peer review on 16 March 2018.19 Based on 
the peer-review feedback, we made minor amendments to 
the initial protocol (online supplementary table 1).
Eligibility criteria
Studies published in peer-reviewed journals were eligible 
for inclusion for this systematic review and meta-anal-
ysis if they met the following participants, intervention, 
comparator, outcome and study design criteria: study 
type was randomised or non-randomised controlled trial, 
cohort or case-control study; intervention was an inject-
able, inactivated whole-virus, split-virus or subunit influ-
enza vaccine; intervention was compared with placebo, 
alternative intervention or no vaccination (no compar-
ison group was required for serological response); study 
population included at least 10 adults aged ≥18 years 
with chronic liver disease of any severity or aetiology 
(by any classification) per comparison group; outcomes 
included all-cause hospitalisation or all-cause mortality 
(or supportive outcomes hospitalisation or mortality 
due to acute respiratory illness, influenza/influenza-like 
illness (ILI) or liver disease complications) or serolog-
ical response to influenza vaccine. We only included 
studies published in English. Review articles, case reports, 
cross-sectional studies, animal studies, editorials, clin-
ical guidelines, studies with liver transplant patients only 
(response to the vaccination and clinical outcomes are 
likely to be strongly influenced by the immunosuppres-
sive medication rather than the status of liver disease), 
studies focused on special populations (such as preg-
nant women, nursing home residents or patients with 
other chronic diseases), test-negative case-control studies 
(where both cases and controls were hospitalised for influ-
enza-related illness/ILI/acute respiratory illness, listed in 
online supplementary table 2) and studies retracted from 
publication were excluded.
Information sources and search strategy
We searched the Cochrane Central Register of Controlled 
Trials, Ovid MEDLINE, Ovid Embase and PubMed (orig-
inally up to 16 July 2017 and later updated up to 20 
January 2019) for articles containing variations of terms 
‘influenza’, ‘influenza’, ‘seasonal’, ‘TIV’, ‘QIV’, ‘3-valent’, 
‘4-valent’, ‘trivalent’ or ‘quadrivalent’ in combination 
with terms ‘vaccine’ or ‘immunisation’ and ‘liver disease’, 
‘hepatic disease’, ‘chronic liver’, ‘chronic hepatic’ or 
‘cirrhosis’. The search also included medical subject 
headings ‘Influenza Vaccines’ (exploded), ‘Influenza, 
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(exploded). The search was filtered by study design, age 
group of participants and publication type. To capture 
studies where patients with liver disease may have been 
included as part of a general population, the search was 
repeated leaving out the liver disease-specific terms and 
with the study design filter restricted to trials only. The 
full search strategy in MEDLINE and the medical subject 
headings for all databases searched are provided in 
online supplementary tables 3 and 4. Electronic searches 
were complemented by manually searching recent influ-
enza vaccine guidelines from Centers for Disease Control 
and Prevention, European Centre for Disease Control 
and Prevention and WHO, and the reference lists of the 
included studies.
Study selection
Titles of the articles identified through the search of the 
studies of influenza vaccination in the general popu-
lation were first prescreened by one reviewer (SH). 
Abstracts and titles of articles meeting the prescreening 
criteria and of all articles identified through the liver 
disease-specific search were then screened by two 
independent reviewers (CP and SH). Studies deemed 
eligible were included in the full-text review by two 
independent reviewers (CP and SH). Disagreements 
were resolved by discussion and the reasons for exclu-
sion were recorded. In case of uncertainty over eligi-
bility, study authors were contacted. Studies for which 
this uncertainty could not be resolved were excluded 
(online supplementary table 5).
Data collection process and data items
Using standardised online forms, two review authors 
(CP and SH) independently and in duplicate extracted 
data on: study participants (inclusion and exclusion 
criteria, method of recruitment/selection, study popu-
lation characteristics), interventions and comparators 
(vaccine type, comparison treatment, dose, route of 
delivery, number and timing of vaccinations/compar-
ator treatments, number of individuals and follow-up 
time in intervention and comparison groups), outcomes 
(definition, time points measured and reported, unit 
of measurement, number of outcomes in the interven-
tion and control group, unadjusted and adjusted effect 
measures, covariates that the effect measures were 
adjusted for, comparisons, missing data and reasons for 
missingness, statistical methods used and processes for 
randomisation), study design (study type, country and 
setting, date of study, study duration, aim of study and 
withdrawals), study quality, study bias, study funding 
and conflicts of interest. We contacted study authors 
to obtain subgroup data, missing data and to clarify 
unclear data. Effect measures were collected in the 
format in which they were reported and transformed 
for analysis as required.
Risk of bias in individual studies
Two review authors (CP and SH) independently assessed 
the risk of bias. We used the Cochrane Collaborations 
tool20 to assess randomised trials and the Newcastle-Ottawa 
Scale21 to assess observational studies. Age, sex, severity 
and aetiology of liver disease and presence of comorbidi-
ties were considered the most important confounders in 
the assessment of observational studies. Additionally, in 
studies of pandemic vaccine effect on clinical outcomes, 
we considered as a potential confounder a previous 
seasonal influenza vaccination in the same season the 
study vaccine was administered. Risk of bias assessment 
in serological studies focused on the study population 
with liver disease. Disagreements over risk of bias were 
resolved by discussion between reviewers.
Summary measures and synthesis of results
Where more than a single study per outcome was iden-
tified and the study designs, protocols and measures 
of treatment effect were considered similar enough to 
produce a meaningful pooled effect, we used random-ef-
fects meta-analysis to summarise the average effects 
of vaccination. For serological vaccine response, we 
compared the haemagglutinisation inhibition (HI) anti-
body responses of patients with liver disease before and 
after vaccination. Comparisons between titres and titre 
ratios were presented as a mean difference (MD) of log 
geometric mean titre (GMT) or log geometric mean titre 
ratio (GMTR) with 95% CIs (titres and ratios were log 
transformed to back to their original scale to obtain SD). 
Seroconversion (defined as the proportion of patients 
whose negative prevaccination serum converted to an HI 
titre >1:40, or who experienced at least a fourfold titre 
increase, after vaccination) and seroprotection (defined 
as the proportion of patients achieving an HI titre of 
>1:40 after vaccination) levels were presented as preva-
lence rates (%) with 95% CI and comparisons between 
rates were presented as risk ratio (RR) with 95% CI. As 
reference levels, for a theoretically adequate response, 
we used 40% for seroconversion and 70% for seroprotec-
tion. Reported rates expressed only as percentages that 
did not correspond to an integer number of patients 
were imputed to the closest possible number of patients 
(closest integer above the reported non-integer for base-
line and closest integer below for effect rates). Response 
measures were presented in categories by virus subtype. 
The vaccine effects on hospitalisation and mortality 
were compared between vaccinated and unvaccinated 
patients with liver disease and presented as a crude RR 
with 95% CI (adjusted effect measures, reported sepa-
rately within results, were available from two studies but 
on different scales). Effect measures from multiple corre-
sponding seasons were combined into an overall measure 
within each study. Presence of frailty bias were evaluated 
by contrasting the effect estimates in and out of influ-
enza season. Person-time was presented as person-seasons 
for seasonal and as person-years for whole-year effect 
estimates. We regarded heterogeneity between studies 
as substantial if τ2 was >0, I2 was >30% and the p value 
for Q-statistic was <0.10. Uncertainty in the estimates of 
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small number of effect estimates are pooled together, was 
not quantified (option not available in the software used). 
Statistical analyses were performed using Stata V.14.0 and 
RevMan V.5.3.
Additional analyses
Subgroup analyses and meta-regression were not carried 
out due to the low number of studies. Sensitivity analyses 
were carried out to investigate whether the serological 
vaccine effects were similar in less severe (non-cirrhotic 
disease) and advanced liver disease (cirrhotic disease) 
comparing response in all patients with that in patients 
with cirrhosis only. We were not able to conduct sensi-
tivity analyses based on aetiology of disease as the study 
populations were mainly of mixed aetiologies. In studies 
that included a healthy control population, we compared 
antibody responses between patients with liver disease 
and the controls.
Risk of bias across the studies
For each of the review outcomes, we evaluated the risk 
of selective outcome reporting bias using the Outcome 
Reporting Bias in Trials classification system.22 Presence 
of publication bias was assessed based on this evalua-
tion and our review design (funnel plots or formal tests 
were not used because of the low number of studies). 
The Grading of Recommendations Assessment, Devel-
opment and Evaluation (GRADE) Working Group 
system23 was used to assess and report the overall quality 
of evidence. In this assessment, we regarded a vaccine 
effect outside of the influenza season (suggesting the 
effect of frailty bias) for clinical outcomes as confounding 
(contributing to study limitations). All assessments were 
completed by two independent reviewers (CP and SH) 
and disagreements were resolved by discussion between 
reviewers.
Patient and public involvement
Patients and the public were not involved in the design or 
planning of this study.
RESulTS
The search of influenza studies in the general population 
provided a total of 10 041 unique study records. After title 
screening, 1607 of these records and 608 unique records 
from the liver disease-specific search were included in the 
abstract and title screening. The full text of 286 studies 
was examined in detail, and of these, 10 studies met the 
inclusion criteria for the review. An additional two studies 
were identified through recent influenza vaccine guide-
lines, making the total number of included studies 12. 
The study flow chart is presented in figure 1.
The included studies consisted of 1 randomised 
controlled trial and 11 cohort studies. Six studies 
included serological outcomes (table 1) and six included 
clinical outcomes (table 2). The studies with serological 
outcomes had low (four studies) to moderate bias (two 
studies) in selection of study population and low (two 
studies), moderate (three studies) and high bias (one 
study) in assessment of the outcomes (bias mostly due 
to lack of description of independent, blind outcome 
assessment). Individual studies with clinical outcomes 
had moderate-to-low risk of bias in selection of the 
study population (in two studies vaccination status was 
self-reported) and low risk of bias in outcome assess-
ment (majority used medical records). In most studies, 
the presence of confounding due to demographic and 
clinical characteristics was unclear (we did not have char-
acteristics for the liver patient subgroups obtained from 
the studies conducted in the general population) and 
the results for control periods (non-influenza periods) 
were available only from two studies. High risk of selec-
tive outcome reporting was suspected in only one clin-
ical study (outcome all-cause mortality) but mainly in 
serological studies (outcome GMTR). Evidence for all 
outcomes was judged as very low quality. Risk of bias and 
selective outcome reporting assessments, and the GRADE 
evidence profile are provided in online supplementary 
tables 6, 7 and 8.
The serological response to influenza vaccine was 
assessed in six studies including a total of 262 patients 
with liver disease (table 1). Each study employed a 
cohort design in which all study participants were vacci-
nated. Mean age of participants with liver disease ranged 
between 42 and 65 years (one study did not report 
baseline characteristics of participants). Three studies 
enrolled exclusively patients with cirrhosis in their liver 
disease group, two studies enrolled both patients with and 
without cirrhosis and one study had separate groups for 
patients with and without cirrhosis. Hepatitis C was the 
main cause of liver disease in three studies and hepatitis 
B in two studies. In one study, aetiology was not specified. 
Four studies immunised the participants with a trivalent 
seasonal vaccine and two used a monovalent pandemic 
vaccine. In all studies, blood samples for postvaccination 
measurements were drawn after minimum of 3 weeks 
and antibody titres measured using a traditional HI assay 
(antibody titre data are provided in online supplemen-
tary table 9).
HI antibody levels of patients with liver disease increased 
in response to vaccination (pooled random-effects MD of 
log GMTs 1.92, 95% CI 1.65 to 2.19) (figure 2). There was 
no substantial heterogeneity between individual estimates 
(τ2=0.04, I2=15%, p=0.28) or levels against influenza A 
and B viruses (p=0.16). Seroconversion rate in patients 
with liver disease to both A/H1N1 and B subtypes was 
clearly above the 40% reference level (pooled random-ef-
fects prevalence for A/H1N1 79.95%, 95% CI 68.19% 
to 89.70% and pooled random-effects prevalence for B 
86.82%, 95% CI 71.87% to 97.07%) and around 40% 
in the case of subtype A/H3N2 (pooled random-effects 
prevalence 55.53%, 95% CI 39.92% to 70.63%). While 
the majority of the studies reported estimates above 40%, 
there was substantial heterogeneity between response 
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Table 1 Characteristics of the included studies on serological response to influenza vaccine
Study Location Design
Participants with liver 
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Ohfuji et al34 Japan Cohort study Patients with chronic HCV 
















Patients with cirrhosis 
and inactive HBV carriers 
(47% cirrhosis, 100% viral 
aetiology in non-cirrhotics, 
aetiologies not provided in 
cirrhotics)


















Patients with cirrhosis 












GMT, geometric mean titre; GMTR, geometric mean titre ratio; HBV, hepatitis B virus; HCV, hepatitis C virus.
I2=72.37% and p=0.01 for subtype A/H3N2; I2=79.99% 
and p<0.01 for subtype B). Seroconversion rate is 
presented in figure 3. Seroprotection rate in patients with 
liver disease was above the 70% reference level (pooled 
random-effects rate 93.88%, 95% CI 87.33% to 98.40%) 
(figure 4). While the majority of studies reported a sero-
protection rate above 70%, there was substantial hetero-
geneity (I2=83.81%, p<0.01) (figure 4). Although some 
studies reported a substantial seroprotection level before 
vaccination, the pooled prevaccination seroprotection 
rate was clearly below 70% (online supplementary figure 
1).
The effectiveness of influenza vaccine in preventing 
all-cause hospitalisation in patients with liver disease was 
investigated in two cohort studies, published in 2014 and 
2016.24 25 A study of 408 participants from Japan24 inves-
tigated pandemic vaccine (against a single virus subtype) 
and enrolled exclusively patients with chronic hepatitis C 
virus (HCV) infection. A study of 8080 participants from 
Taiwan25 investigated seasonal vaccine (against multiple 
virus subtypes) exclusively in patients with chronic hepa-
titis B virus (HBV) infection. In the study of patients with 
HCV infection, patients were prospectively recruited from 
those who were under clinical follow-up for their liver 
disease but vaccination status was self-reported.24 In the 
study of patients with HBV infection, both liver disease 
and vaccination status were determined from electronic 
medical claim records.25 One study presented results for 
one influenza season and the other for an entire year 
after vaccination and pooled the results from a period 
of 9 years (figure 5). Both studies compared the rate of 
all-cause hospital admission (first incidence) between 
vaccinated and unvaccinated individuals.
Vaccinated patients with HCV were no less likely to be 
hospitalised than unvaccinated patients during an influ-
enza season after pandemic influenza A vaccination (RR 
0.57, 95% CI 0.24 to 1.37, risk difference [RD] −0.03, 
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Table 2 Characteristics of the included studies on clinical outcomes after influenza vaccination
Study Location Design
Participants with liver 
disease
Sample size 
(patients with liver 
disease) Study period Outcomes
Campitelli et 
al26
Canada Cohort study Patients with chronic 

















Spain Cohort study Patients with cirrhosis 
among the community-












Ohfuji et al24 Japan Cohort study Hospital outpatients 














and outpatients with 












Su et al25 Taiwan Cohort study Hospital outpatients 




















Spain Cohort study Patients with cirrhosis 
among the community-














HBV, hepatitis B virus; HCV, hepatitis C virus.
outside the influenza season was not measured. Adjusting 
the effect estimate (for chronic comorbidities, steroid 
treatment within the preceding 6 months and albumin 
level), calculated in the study as the OR (crude OR 0.55, 
95% CI 0.22 to 1.39), adjusted OR 0.43, 95% CI 0.16 
to 1.17), did not reveal a significant effect.24 Seasonal 
vaccination, however, was associated with a drop from 
205/1000 patients to 149/1000 patients being hospital-
ised during a full year of follow-up (RD −0.06, 95% CI 
−0.07 to –0.04). Vaccinated patients with HBV were 27% 
less likely to be admitted to the hospital than unvacci-
nated patients (RR 0.73, 95% CI 0.66 to 0.80).25 Both 
the crude and the adjusted time-to-event estimate that 
accounted for cirrhosis status, age, sex, pneumococcal 
vaccine, comorbidities and recent hospitalisation, calcu-
lated in the study as the HR, showed a protective effect 
(crude HR 0.68, 95% CI 0.62 to 0.76, adjusted HR 0.56, 
95% CI 0.50 to 0.62).25 Based on a Kaplan-Meier plot, 
the difference in event-free survival probability between 
vaccinated and unvaccinated was established during the 
influenza season, approximately within the first 3 months 
after vaccination.25 The effect of influenza vaccine on 
cause-specific hospitalisation was investigated in two 
studies.25 26 A cohort study from Canada, published in 
2010, measured acute respiratory illness-related hospi-
talisation during influenza season (defined as influ-
enza/pneumonia hospitalisation) using medical claims 
and hospital records.26 A total of 329 patients with liver 
disease were included as part of a general population, 
however, as there were five or fewer hospitalisation events 
in both groups, the study authors were unable to release 
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Figure 2 Serological response to influenza vaccination: mean difference in log haemagglutinisation inhibition (HI) antibody 
geometric mean titres (GMTs) before and after vaccination. Sayyad et al (2012a) includes patients with cirrhosis and Sayyad et 
al (2012b) includes patients without cirrhosis.
Figure 3 Serological response to influenza vaccination: 
seroconversion rate after vaccination. Sayyad et al (2012a) 
includes patients with cirrhosis and Sayyad et al (2012b) 
includes patients without cirrhosis. ES=effect size.
Figure 4 Serological response to influenza vaccination: 
seroprotection rate after vaccination. Sayyad et al (2012a) 
includes patients with cirrhosis and Sayyad et al (2012b) 
includes patients without cirrhosis. ES=effect size.
communication). A liver disease complication-related 
hospitalisation outcome was included in the Taiwanese 
study of patients with HBV.25 Vaccinated patients with 
liver disease were 57% less likely to be admitted to 
hospital for unspecified septicaemia, bacteraemia and 
viraemia than unvaccinated patients (RR 0.43, 95% CI 
0.31 to 0.59). Vaccination was associated with a fall from 
26/1000 patients to 11/1000 patients being hospitalised 
(RD −0.02, 95% CI −0.02 to –0.01). It appeared, however, 
that a difference in event-free survival probability was not 
established during the influenza season (Kaplan-Meier 
plot).25 No studies with the outcome influenza illness/
ILI-related hospitalisation were identified.
The effectiveness of influenza vaccine in preventing 
all-cause mortality in patients with liver disease was inves-
tigated in five cohort studies,25–28 published between 2007 
and 2016. Only the Taiwanese study of patients with HBV 
enrolled exclusively patients with liver disease.25 Two 
studies from Spain27 28 and one from Canada26 enrolled 
patients with liver disease as part of the general, commu-
nity-dwelling population. All studies ascertained liver 
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Figure 5 Effect of influenza vaccine on clinical outcomes: all-cause hospitalisation in vaccinated compared with unvaccinated 
patients with liver disease. Ohfuji et al24 investigated the effect of pandemic (monovalent) vaccine and SU et al25 investigated the 
effect of seasonal vaccine (against three or more virus subtypes).
Figure 6 Effect of influenza vaccine on clinical outcomes: all-cause mortality in vaccinated compared with unvaccinated 
patients with liver disease.
health or medical claim records. In one study, the record-
based vaccination status was based on self-reporting. The 
Spanish studies followed patients over multiple seasons 
from the start of the study allowing them to contribute 
to both the unvaccinated and vaccinated follow-up 
time for different seasons,27 28 whereas the other two 
studies followed patients up for a single season/year,25 26 
although this was over multiple seasons/years. All studies 
compared all-cause mortality rates between vaccinated 
and unvaccinated individuals.
Results are presented in figure 6. Vaccinated patients 
were no less likely to die during influenza season (pooled 
random effects RR 0.80, 95% CI 0.43 to 1.50, RD −0.001, 
95% CI −0.01 to 0.01), or the entire year (pooled random 
effects RR 0.41, 95% CI 0.11 to 1.52, RD −0.06, 95% CI 
−0.08 to 0.04). All the studies that contributed to the 
influenza season-specific estimate reported non-sig-
nificant effects and there was no substantial heteroge-
neity (τ2=0.12, I2=33.00%, p=0.23). The studies that 
contributed to the whole-year estimate were substan-
tially heterogeneous (τ2=0.83, I2=94.00%, p<0.00), with 
the smaller Spanish study28 reporting a non-signifi-
cant effect (personal communication) and the larger 
Taiwanese study reporting a large protective effect (RR 
0.22, 95% CI 0.17 to 0.28).25 The Spanish study reported 
no effect outside the influenza period (RR 0.52, 95% CI 
0.15 to 1.83). The Canadian study also measured the 
effect outside the non-influenza period but as there were 
five or fewer deaths in both groups, the authors were 
unable to provide the results (institution’s data policy, 
personal communication). Based on a Kaplan-Meier 
plot presented in the Taiwanese study, the difference in 
survival probability was mainly established approximately 
in the first 5 months after vaccination,25 however, it was 
not clear whether the increase in death rate fully levelled 
off after the influenza season and it may be that this to 
some extent contributed to the size of the yearly effect 
estimate in this study. The effect of influenza vaccine on 
the rate of cause-specific mortality was investigated in 
one study.29 The effect of influenza vaccine in preventing 
influenza illness/ILI-related mortality was included as an 
outcome in a South Korean randomised controlled trial 
of patients with cirrhosis published in 2007.29 No deaths 
due to laboratory-confirmed influenza occurred among 
the 175 vaccinated or the 90 unvaccinated patients during 
the influenza season.29 No studies investigating mortality 
related to acute respiratory illness or liver disease compli-
cations were identified.
To understand whether the vaccine effects were 
different based on the patients’ cirrhosis status, we 
conducted sensitivity analyses. The serological response 
in patients with cirrhosis did not differ from the results 
of our main analyses (online supplementary figures 2-5). 
We did not have the data and therefore were not able to 
conduct similar analyses for the clinical outcomes.
In addition to comparing the vaccine effects within 
patients with liver disease, the studies of serological 
response (5/6 studies) also compared the outcomes 
between patients with liver disease and healthy controls 
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Table 3 Summary of findings for clinical outcomes
Outcome
Patients: adults with chronic liver disease
Setting: general population




















80 per 1000 46 per 1000 
(19–110)






205 per 1000 150 per 1000 
(135–164)
0.73 (0.66, 0.80) 27% (20%, 
34%)‡






17 per 1000 
person-seasons
14 per 1000 
person-seasons 
(7–26)






85 per 1000 
person-seasons
35 per 1000 
person-seasons 
(9–129)
0.41 (0.11, 1.52) Not significant 8405 person-years (2 
observational studies)
Very low**
Effectiveness of influenza vaccination in preventing all-cause hospitalisation and all-cause mortality in adults with chronic liver disease.
*Median risk in unvaccinated across the studies.
†Rated down from low to very low based on study limitations, imprecision of the estimate and suspicion of publication bias.
‡Could be applicable to patients with HBV only as the study only enrolled patients with HBV.
§Rated down from low to very low based on suspicion of publication bias.
¶Rated down from low to very low based on study limitations, inconsistency in absolute rates, imprecision of the estimate and suspicion of 
publication bias.
**Rated down from low to very low based on study limitations, imprecision of the estimate and suspicion of publication bias.
GRADE, Grading of Recommendations Assessment, Development and Evaluation; HBV, hepatitis B virus.
before or after vaccination, seroconversion rate and 
seroprotection rate of patients with liver disease did not 
differ from those of healthy individuals. Prevaccination 
to postvaccination titre ratios (GMTRs) reported were 
similar between patients with liver disease and healthy 
individuals except for influenza subtype A/H3N2 where 
the mean fold-increase in antibody levels of patients with 
liver disease was lower than that of healthy individuals. 
The pooled results for these comparisons are provided in 
online supplementary figures 6-11. The studies on clinical 
outcomes in patients with liver disease did not include 
healthy comparison groups and while we did not seek 
these data from the studies that included patients with 
liver disease as part of a general population, the all-cause 
mortality results in the entire general population can be 
found in online supplementary table 10.
DISCuSSIOn
Six cohort studies from three continents (Asia, Europe 
and North America) investigated the serological 
vaccine response in patients with liver disease. Two 
cohort studies and one randomised controlled trial, all 
from Asia, investigated the vaccine effect on hospital-
isation and/or mortality in patients with liver disease 
exclusively. In addition, there are at least three cohort 
studies, two from Europe and one from North America, 
that have assessed the vaccine effect on these outcomes 
in a general community-dwelling elderly population 
including a subgroup with liver disease. Overall, the 
available evidence suggests that while influenza vaccine 
may not protect against all-cause mortality, it triggers 
an effective antibody response and may reduce the risk 
of all-cause hospitalisation in patients with liver disease 
(findings for clinical outcomes summarised in table 3, 
maximum quality obtainable is ‘low’ as all included 
studies are non-randomised).
A previous systematic review14 on the effectiveness 
of inactivated influenza vaccine in different at-risk 
target groups identified only one randomised study in 
patients with liver disease. This study of 311 patients 
with cirrhosis, also included in our current review, 
found seasonal influenza vaccine effective against labo-
ratory-confirmed influenza but not against ILI.29 The 
study included hospitalised patients and could not 
investigate vaccine effectiveness against hospitalisation. 
Vaccine effect on influenza-related mortality was investi-
gated, however, no deaths occurred during the study. It 
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to the vaccine. Other factors that may have affected the 
clinical outcomes include frailty bias, competing risks 
(in case of our secondary, cause-specific outcomes) and 
differences in previous vaccinations, social support, 
healthcare system, lifestyle and in the severity or type of 
liver disease between the vaccinated and unvaccinated 
populations. Serological outcomes may have been 
further affected by variation of the antibody assays.
The data presented are predominantly from patients 
with viral liver disease. We cannot therefore be certain 
that our findings are applicable to patients with liver 
disease caused by alcohol, obesity or other non-viral 
factors. While sensitivity analyses showed that compared 
with non-cirrhotic liver disease, having cirrhosis did not 
worsen the antibody response to the vaccine, most data 
in the analyses of clinical outcomes come from patients 
with a milder form of liver disease than cirrhosis. We 
might expect that in severe liver disease complications 
from influenza are more frequent and we may have seen 
more outcome events if more patients with cirrhosis 
were included. Given the proxy effectiveness in patients 
with cirrhosis indicated by the antibody responses, this 
would mean that our study may have somewhat under-
estimated the true protective effect against clinical 
outcomes. However, all our data on the hospitalisation 
outcome are from high-income Asian countries and it 
is possible that the protective vaccine effect may not 
extend to populations from other geographical and 
income settings with different prevalence of comorbid-
ities, age distribution, influenza seasonality and vaccine 
formulation used.
Our review has several strengths. It was conducted 
in a transparent way following established guidelines 
and a prospectively specified protocol. The search was 
conducted over multiple databases and we searched for 
both studies in patients with liver disease and studies in 
which patients with liver disease were included as part of 
the general population. To reduce the risk of missing rele-
vant studies and relevant data and to increase the objec-
tivity of the review, two independent reviewers screened 
the studies, extracted data and assessed the risk of bias. 
We studied all-cause outcomes to take into account the 
complex interplay of a chronic condition and acute infec-
tions. An underlying diagnosis of chronic liver disease 
may influence how cause of death and hospitalisation is 
recorded. This potentially reduces the number of cases 
that are attributed to influenza and solely investigating 
diagnoses of influenza is likely to substantially underesti-
mate the impact of the vaccine.
There are also limitations to our review. The meta-anal-
yses combine data from studies that differ in terms of 
patient population, outcome definitions and vaccine 
used. For the studies that included patients with liver 
disease as part of the general population, we had very 
limited information about the baseline characteristics 
of the patient with liver disease subgroup. In addition, 
despite the comprehensive search, publication bias, 
restriction on publication language and varying response 
to queries about data on liver disease subgroups may have 
affected the effects observed. We were not able to employ 
translation services and may have omitted relevant studies 
published in languages other than English from countries 
such as China where influenza vaccines are manufactured 
and liver disease is a significant public health challenge. 
A number of studies potentially included patients with 
liver disease as part of a wider study population but were 
unable to obtain confirmation and liver disease subgroup 
data from the study authors. Finally, the body of evidence 
identified in this review is limited both in quantity and 
quality, leaving room for uncertainty around the effects 
of the vaccination. The low quality is partly due to the 
non-randomised design of the included studies. This 
limitation may persist also in future reviews as conducting 
randomised controlled trials in a high-risk population are 
ethically challenging.
Evidence from mainly patients with viral liver disease 
suggests that underlying liver disease does not prevent 
patients from mounting an antibody response to influ-
enza vaccine and similar proxy effectiveness is seen both 
in patients with and without cirrhosis. We also identi-
fied a protective influenza vaccine effect against yearly 
all-cause hospitalisation in patients with viral liver disease. 
Assuming this effect—estimated in a large cohort study of 
over 8000 patients—is due to the vaccine, seasonal influ-
enza vaccination of 14–24 patients with viral liver disease 
could prevent one hospitalisation per year. It is uncertain 
whether the estimated effects extend to patients with liver 
disease of other than viral origin. No protective effect 
against all-cause mortality was found.
Current uptake of seasonal influenza vaccination is 
low. A recent systematic review identified low perceived 
vaccine effectiveness, and low concern and perceived risk 
of severe influenza infection as the most common barriers 
for seasonal influenza vaccination in patients with chronic 
illness.30 Ideally, the evidence for influenza vaccine effective-
ness in liver disease would come from a large randomised 
vaccine trial in patients with liver disease. In the absence 
of this evidence, we must rely on proxy estimates for effec-
tiveness from serological studies and evidence on clinical 
outcomes from observational studies. The best available 
evidence on the effectiveness of influenza vaccine in liver 
disease, summarised in this review, shows both proxy effec-
tiveness and protection against all-cause hospitalisation. 
The limited quantity and quality of this evidence means that 
the protective vaccine effect may be uncertain. However, 
considering the high risk of serious health outcomes from 
influenza infection in patients with liver disease and the 
safety and low cost of vaccination, overall the potential 
benefits of seasonal vaccination both to patients and the 
healthcare systems are likely to outweigh the costs and 
risks associated with vaccination. Wider collection of adult 
vaccination data and studies focused on patients with liver 
disease, using large databases linking routinely collected 
data on vaccinations and health, may allow us to address 
the remaining uncertainty about the effects of influenza 
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